NDA 210655 · Indivior
Perseris Kit
Risperidone · Subcutaneous
DiscontinuedLast checked: Nov 20, 2026Latest source record: Apr 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Jul 27, 2018
Approved uses
2
Original approval plus efficacy supplements
Registered trials
514
127 Phase 3, 14 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 15, 2022 Supplement 10 · Efficacy LetterLabel
- Jul 27, 2018 Original approval · Type 3 - New Dosage Form LetterLabelReview
2 products under this application
- PERSERIS KIT · RISPERIDONE 120MG · FOR SUSPENSION, EXTENDED RELEASE, SUBCUTANEOUS · Discontinued
- PERSERIS KIT · RISPERIDONE 90MG · FOR SUSPENSION, EXTENDED RELEASE, SUBCUTANEOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Risperidone" as an intervention, any sponsor and status, largest first.
- Safety Study of Sertindole Versus Risperidone Under Normal Conditions of UsePivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT00856583 · 9,809 participants · Start Jul 2002 · Primary completion Feb 2008
Drug: Sertindole; Risperidone · For: Schizophrenia
- Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00012558 · 5,000 participants · Start Sep 1998
Drug: lithium; valproate and 6 more · For: Bipolar Disorder
Sites: Stanford, California; Denver, Colorado; Boston, Massachusetts · 11 sites in all
- Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia IndividualsStatus unknown
Tianjin Medical University General HospitalAcademic, hospital or other
NCT03790085 · 2,700 participants (planned) · Start Sep 1, 2018 · Primary completion Jun 30, 2020
Drug: Risperidone; Olanzapine and 1 more · For: Schizophrenia; Major Depressive Disorder; Anxiety Disorders
Sites: Tianjin, China
- Metabolic Profile and Anthropometric Changes in SchizophreniaPivotal-lookingCompleted
Central Institute of Psychiatry, Ranchi, IndiaAcademic, hospital or other
NCT00534183 · 2,006 participants · Start Jun 2006
Drug: Olanzapine; Risperidone and 1 more · For: Metabolic Syndrome; Diabetes; Obesity
Sites: Ranchi, India
- The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With SchizophreniaPivotal-lookingCompleted
Beijing HuiLongGuan HospitalAcademic, hospital or other
NCT04076371 · 1,640 participants · Start Jan 2012 · Primary completion Dec 2018
Drug: olanzapine-sertraline combination; only olanzapine and 6 more · For: Schizophrenia
- CATIE- Schizophrenia TrialPivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00014001 · 1,600 participants · Start Dec 2000
Drug: perphenazine; olanzapine and 5 more · For: Schizophrenia
Sites: Chula Vista, California; Los Angeles, California; Orange, California · 54 sites in all
- A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic SchizophreniaPivotal-lookingCompleted
Janssen, LPJohnson & Johnson (Janssen) (JNJ)
NCT00249119 · 1,579 participants
Drug: risperidone · For: Schizophrenia; Psychotic Disorder
- Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With SchizophreniaPivotal-lookingCompleted
Central South UniversityAcademic, hospital or other
NCT00654576 · 1,400 participants (planned) · Start Feb 2005 · Primary completion Dec 2007
Drug: Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole · For: Schizophrenia
Sites: Changsha, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Efficacy, acceptability and side-effects of oral versus long-acting- injectables antipsychotics: Systematic review and network meta-analysis.
Wang D, Schneider-Thoma J, Siafis S, et al. · Eur Neuropsychopharmacol 2024 · Systematic Review, Network Meta-Analysis
- Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis.
Krause M, Zhu Y, Huhn M, et al. · Eur Arch Psychiatry Clin Neurosci 2018 · Meta-Analysis, Systematic Review
- Guiding safer risperidone prescribing in Alzheimer's disease with therapeutic drug monitoring.
Roughley M, Mena C, Howard R, et al. · Br J Clin Pharmacol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Antipsychotics for delirium.
Lonergan E, Britton AM, Luxenberg J, et al. · Cochrane Database Syst Rev 2007 · Meta-Analysis, Systematic Review
- Pharmacological and non-pharmacological interventions for irritability in autism spectrum disorder: a systematic review and meta-analysis with the GRADE assessment.
Choi H, Kim JH, Yang HS, et al. · Mol Autism 2024 · Meta-Analysis, Systematic Review
Sponsor: Indivior
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.